Improving healthcare for all

Ganymed Robotics raises €21 million for its surgical robotic assistant dedicated to Total Knee Arthroplasty

11 Oct 2022

Octopus raises €3 million to reconcile the quality of indoor air and the energy performance of buildings

The Lille-based startup created in 2017 raised €3 million euros on July 4. The operation was led by Swen Capital Partners and Matmut Innovation, with Bouygues Construction Venture and BTP Capital Investissement, along with Nord Création and Nord France Amorçage. It will help accelerate the growth of Octopus Lab and continue the roll-out of Indalo Supervision, a predictive software service dedicated to the smart management of buildings to guarantee their environmental performance and protect the health of those living and working inside.

Ludocare raises €4.2 million for its connected medical companion for very young children

The round of financing was announced on July 4 and completed with Karista and Bpifrance, which is participating via its Patient Autonome fund, and the French Tech Seed fund, managed on behalf of the State by Bpifrance within the framework of France 2030. These funds are expected to finance an upcoming large-scale clinical study and broaden the scope of its solution. The Lyon-based startup established in 2017 has designed Joe, a robot that accompanies and motivates very young children suffering from chronic illnesses such as asthma, so that they follow their treatment conscientiously, and are rewarded at the end (game, story, song,…).

Ganymed Robotics raises €21 million for its surgical robotic assistant dedicated to Total Knee Arthroplasty

On July 7, 2022, the French company created in 2018 made public a series B round of financing of €21 million, led by Cathay Health, with the participation of Crédit Mutuel Innovation, Kurma Partners and BNP Paribas Développement. The funds collected will enable the company to finalize the development and prepare the launch of its surgical robot assistant dedicated to Total Knee Arthroplasty (TKA), and to roll out its operations in the United States.

Visiomed raises €3.6 million via a participatory bond issue

On July 12, 2022, Visiomed Group launched the first participatory bond issue carried out by a company listed on Euronext Growth in Paris, with a fundraising objective of at least €2.5 million. At the end of August, the amount subscribed via the Equisafe Invest platform at closing had reached €3.6 million. In total, 3,640,592 bonds, with a denomination per unit of 1 euro were issued and subscribed by 486 investors. This financing will enable the company, which was created in 2007, to pursue its development strategy by accelerating the expansion of Smart Salem (the only digitalized medical center accredited by the Dubai Ministry of Health), repositioning BewellConnect (its connected healthcare subsidiary which is responsible in particular for the marketing of the VisioCheck mobile teleconsultation station) and enabling synergies and external growth opportunities.

Thabor Therapeutics closes a round of financing of €2 million for its chronic mucosal inflammatory diseases treatment

On July 15, 2022 the Paris-based company, established in 2021, disclosed that it had received €2 million from Bpifrance, as part of the Deeptech plan. This funding by Bpifrance is the next stage in the series A round of financing planned for the fourth quarter of 2022. It will serve to accelerate R&D to allow the industrial development of the monoclonal antibodies at the heart of an innovative therapy for patients suffering from chronic mucosal inflammatory diseases. 

Néovacs raises €2 million for its Kinoïde research program

The €2 million were raised on August 23, 2022 by drawing 2 tranches of OCEANE-BSA, with a nominal value of €1,000,000, subscribed by European High Growth Opportunities Securitization Fund using its Investor Call option. The net proceeds of this operation (€1,920,000) will be allocated to the financing of the Kinoïde allergy research program and to strengthen the capacity to invest in promising projects, both in the development of drug candidates and medical devices. Founded in 1993, Néovacs is a French biotech company, specializing in therapeutic vaccines that target the treatment of auto-immune diseases.

What are you looking for?